China Biologic Products Inc (CBPO) : Indus Capital Partners scooped up 175,918 additional shares in China Biologic Products Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 378,518 shares of China Biologic Products Inc which is valued at $43.5 Million.China Biologic Products Inc makes up approximately 6.27% of Indus Capital Partners’s portfolio.
Other Hedge Funds, Including , Bogle Investment Management L P De sold out all of its stake in CBPO during the most recent quarter. The investment firm sold 88,870 shares of CBPO which is valued $10.2 Million.Mirae Asset Global Investments Ltd. boosted its stake in CBPO in the latest quarter, The investment management firm added 48,977 additional shares and now holds a total of 57,589 shares of China Biologic Products Inc which is valued at $6.6 Million. China Biologic Products Inc makes up approx 0.18% of Mirae Asset Global Investments Ltd.’s portfolio. Manufacturers Life Insurance Company The added CBPO to its portfolio by purchasing 176,003 company shares during the most recent quarter which is valued at $20.2 Million. China Biologic Products Inc makes up approx 0.03% of Manufacturers Life Insurance Company The’s portfolio.Cibc Asset Management Inc boosted its stake in CBPO in the latest quarter, The investment management firm added 3,690 additional shares and now holds a total of 14,230 shares of China Biologic Products Inc which is valued at $1.6 Million. China Biologic Products Inc makes up approx 0.01% of Cibc Asset Management Inc’s portfolio.
China Biologic Products Inc closed down -0.64 points or -0.55% at $114.84 with 2,77,948 shares getting traded on Wednesday. Post opening the session at $115.55, the shares hit an intraday low of $114.04 and an intraday high of $115.86 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, China Biologic Products Inc reported $1.09 EPS for the quarter, beating the analyst consensus estimate by $ 0.21 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.88. The company had revenue of $85.60 million for the quarter.The company’s revenue was up 21.6% compared to the same quarter last year.
Many Wall Street Analysts have commented on China Biologic Products Inc. China Biologic Products Inc was Downgraded by Credit Suisse to ” Neutral” on Mar 1, 2016.
China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).